SIGHT SCIENCES INC (SGHT) Stock Fundamental Analysis

NASDAQ:SGHT • US82657M1053

5.25 USD
-0.11 (-2.05%)
At close: Feb 24, 2026
5.25 USD
0 (0%)
After Hours: 2/24/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall SGHT gets a fundamental rating of 3 out of 10. We evaluated SGHT against 185 industry peers in the Health Care Equipment & Supplies industry. The financial health of SGHT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, SGHT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year SGHT has reported negative net income.
  • In the past year SGHT has reported a negative cash flow from operations.
  • SGHT had negative earnings in each of the past 5 years.
  • SGHT had a negative operating cash flow in each of the past 5 years.
SGHT Yearly Net Income VS EBIT VS OCF VS FCFSGHT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • SGHT has a Return On Assets of -39.66%. This is in the lower half of the industry: SGHT underperforms 63.24% of its industry peers.
  • The Return On Equity of SGHT (-71.72%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -39.66%
ROE -71.72%
ROIC N/A
ROA(3y)-36.62%
ROA(5y)-36%
ROE(3y)-52.97%
ROE(5y)-61.55%
ROIC(3y)N/A
ROIC(5y)N/A
SGHT Yearly ROA, ROE, ROICSGHT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • With an excellent Gross Margin value of 86.83%, SGHT belongs to the best of the industry, outperforming 96.22% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SGHT has grown nicely.
  • The Profit Margin and Operating Margin are not available for SGHT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y3.51%
SGHT Yearly Profit, Operating, Gross MarginsSGHT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • SGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SGHT has been increased compared to 1 year ago.
  • The number of shares outstanding for SGHT has been increased compared to 5 years ago.
  • Compared to 1 year ago, SGHT has a worse debt to assets ratio.
SGHT Yearly Shares OutstandingSGHT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SGHT Yearly Total Debt VS Total AssetsSGHT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • SGHT has an Altman-Z score of -0.88. This is a bad value and indicates that SGHT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of SGHT (-0.88) is comparable to the rest of the industry.
  • SGHT has a Debt/Equity ratio of 0.62. This is a neutral value indicating SGHT is somewhat dependend on debt financing.
  • SGHT has a Debt to Equity ratio of 0.62. This is in the lower half of the industry: SGHT underperforms 64.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -0.88
ROIC/WACCN/A
WACC10.32%
SGHT Yearly LT Debt VS Equity VS FCFSGHT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 9.60 indicates that SGHT has no problem at all paying its short term obligations.
  • SGHT's Current ratio of 9.60 is amongst the best of the industry. SGHT outperforms 90.27% of its industry peers.
  • SGHT has a Quick Ratio of 8.93. This indicates that SGHT is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 8.93, SGHT belongs to the best of the industry, outperforming 91.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.6
Quick Ratio 8.93
SGHT Yearly Current Assets VS Current LiabilitesSGHT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 11.76% over the past year.
  • The Revenue has decreased by -4.39% in the past year.
  • The Revenue has been growing by 27.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)11.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
Revenue 1Y (TTM)-4.39%
Revenue growth 3Y17.72%
Revenue growth 5Y27.88%
Sales Q2Q%-1.25%

3.2 Future

  • SGHT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.57% yearly.
  • SGHT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.00% yearly.
EPS Next Y18.04%
EPS Next 2Y18.6%
EPS Next 3Y16.08%
EPS Next 5Y10.58%
Revenue Next Year-4%
Revenue Next 2Y3.11%
Revenue Next 3Y6.33%
Revenue Next 5Y9%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SGHT Yearly Revenue VS EstimatesSGHT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
SGHT Yearly EPS VS EstimatesSGHT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SGHT. In the last year negative earnings were reported.
  • Also next year SGHT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGHT Price Earnings VS Forward Price EarningsSGHT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGHT Per share dataSGHT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • SGHT's earnings are expected to grow with 16.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.6%
EPS Next 3Y16.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SGHT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SIGHT SCIENCES INC

NASDAQ:SGHT (2/24/2026, 8:00:02 PM)

After market: 5.25 0 (0%)

5.25

-0.11 (-2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners49.61%
Inst Owner Change12.39%
Ins Owners18.82%
Ins Owner Change2.82%
Market Cap277.57M
Revenue(TTM)76.05M
Net Income(TTM)-46.11M
Analysts80
Price Target9.54 (81.71%)
Short Float %2.63%
Short Ratio3.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.11%
Min EPS beat(2)14.4%
Max EPS beat(2)37.82%
EPS beat(4)3
Avg EPS beat(4)11.04%
Min EPS beat(4)-10.81%
Max EPS beat(4)37.82%
EPS beat(8)5
Avg EPS beat(8)9.01%
EPS beat(12)9
Avg EPS beat(12)11.07%
EPS beat(16)11
Avg EPS beat(16)7.09%
Revenue beat(2)2
Avg Revenue beat(2)7.73%
Min Revenue beat(2)5.48%
Max Revenue beat(2)9.98%
Revenue beat(4)3
Avg Revenue beat(4)3.47%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)9.98%
Revenue beat(8)4
Avg Revenue beat(8)1.09%
Revenue beat(12)5
Avg Revenue beat(12)-0.07%
Revenue beat(16)9
Avg Revenue beat(16)1.15%
PT rev (1m)0%
PT rev (3m)53.7%
EPS NQ rev (1m)0.88%
EPS NQ rev (3m)4.12%
EPS NY rev (1m)0.42%
EPS NY rev (3m)18.23%
Revenue NQ rev (1m)-0.55%
Revenue NQ rev (3m)-0.59%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)4.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.65
P/FCF N/A
P/OCF N/A
P/B 4.32
P/tB 4.32
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS1.44
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.66%
ROE -71.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.83%
FCFM N/A
ROA(3y)-36.62%
ROA(5y)-36%
ROE(3y)-52.97%
ROE(5y)-61.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.23%
GM growth 5Y3.51%
F-Score3
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 93.15%
Cap/Sales 0.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.6
Quick Ratio 8.93
Altman-Z -0.88
F-Score3
WACC10.32%
ROIC/WACCN/A
Cap/Depr(3y)106.51%
Cap/Depr(5y)124.16%
Cap/Sales(3y)0.94%
Cap/Sales(5y)1.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
EPS Next Y18.04%
EPS Next 2Y18.6%
EPS Next 3Y16.08%
EPS Next 5Y10.58%
Revenue 1Y (TTM)-4.39%
Revenue growth 3Y17.72%
Revenue growth 5Y27.88%
Sales Q2Q%-1.25%
Revenue Next Year-4%
Revenue Next 2Y3.11%
Revenue Next 3Y6.33%
Revenue Next 5Y9%
EBIT growth 1Y9.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year39.75%
EBIT Next 3Y18.36%
EBIT Next 5YN/A
FCF growth 1Y44.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.27%
OCF growth 3YN/A
OCF growth 5YN/A

SIGHT SCIENCES INC / SGHT FAQ

What is the fundamental rating for SGHT stock?

ChartMill assigns a fundamental rating of 3 / 10 to SGHT.


Can you provide the valuation status for SIGHT SCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to SIGHT SCIENCES INC (SGHT). This can be considered as Overvalued.


Can you provide the profitability details for SIGHT SCIENCES INC?

SIGHT SCIENCES INC (SGHT) has a profitability rating of 2 / 10.


What is the financial health of SIGHT SCIENCES INC (SGHT) stock?

The financial health rating of SIGHT SCIENCES INC (SGHT) is 4 / 10.